Biotech News
Immatics Announces Third Quarter 2026 Financial Results and Business Update
Enrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203) is on track to complete the required randomizations by year-end to support final analysis for the primary PFS endpoint SUPRAME topline data disclosure remains expected in H1 2027, followed by BLA submission in
